Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
ELVN Enliven Therapeutics
- 23.150
- +0.150+0.65%
Close Dec 13 16:00 ET
- 23.150
- 0.0000.00%
Post 16:00 ET
1.13BMarket Cap-12.84P/E (TTM)
23.710High22.610Low153.66KVolume23.190Open23.000Pre Close3.56MTurnover0.62%Turnover RatioLossP/E (Static)48.86MShares30.03052wk High3.92P/B575.59MFloat Cap10.90052wk Low--Dividend TTM24.86MShs Float250.840Historical High--Div YieldTTM4.78%Amplitude3.896Historical Low23.159Avg Price1Lot Size
Enliven Therapeutics News
We're Hopeful That Enliven Therapeutics (NASDAQ:ELVN) Will Use Its Cash Wisely
BTIG Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $42
Enliven Therapeutics' ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $36
Strong Buy Recommendation for Enliven Therapeutics: Promising Efficacy and Strategic Positioning in CML Market
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40
Express News | Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40
Enliven Therapeutics Reports Q3 Results and Clinical Progress
Express News | Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32
Enliven Therapeutics: Promising Clinical Developments and Robust Financial Position Justify Buy Rating
Express News | Enliven Therapeutics Inc: Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026
Enliven Therapeutics | 10-Q: Q3 2024 Earnings Report
Enliven Therapeutics | 8-K: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Express News | Enliven Therapeutics Q3 2024 GAAP EPS $(0.48) Beats $(0.49) Estimate
Express News | Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Express News | Enliven Therapeutics Q3 Income From Operations USD -27.068 Million
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Enliven Therapeutics Price Target Announced at $36.00/Share by Jones Trading
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $36
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.